echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Development of pancreatic cancer drugs QD394 and QD394-Me: Targeting GPX4 to mediate tumor cell death

    Development of pancreatic cancer drugs QD394 and QD394-Me: Targeting GPX4 to mediate tumor cell death

    • Last Update: 2021-07-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    Further proteomics studies have shown that QD394 can effectively reduce the expression of proteins in mitochondria (mainly down-regulate the mitochondrial proteins LRPPRC and PNPT1)
    .


    Figure 9 Combined use with FDA approved drugs


    The combination of QD394 and existing FDA-approved drugs (including Napabucasin, As2O3 and olaparib) found that QD394 and these drugs showed a certain synergistic anti-cancer ability
    .


    Figure 10 Pharmacokinetic data


    The above-mentioned research shows that QD394 has significant potential for the development of pancreatic cancer drugs, but follow-up pharmacokinetic studies show that QD394 is poor in plasma stability, with a half-life of only 6 minutes
    .
    Therefore, researchers have further developed QD394-Me with better pharmacokinetic data (see Figure 11 for the structural formula), and its plasma half-life can reach more than 120 minutes (Figure 10)
    .


    Figure 11.
    Development and mechanism of QD394-Me


    The efficacy and function evaluation of QD394-Me showed that the mechanism of action of QD394-Me is similar to that of QD394, and at the same time it has better efficacy
    .


    Figure 12 QD394-Me drug efficacy and function evaluation


    The development of pancreatic cancer from QD394 to QD394-Me not only provides two drug molecules, QD394 and QD394-Me, but also provides the possibility for further pancreatic cancer drug development; at the same time, the combination of this type of drug molecule with existing marketed drug molecules can show It has a synergistic effect and has the potential for development of combination drugs
    .
    It is expected that such drug molecules will be launched as soon as possible to benefit the majority of pancreatic cancer patients
    .


    references:


    1.
    A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species, 2020.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.